{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:09:22Z","timestamp":1789427362066,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102954"],"award-info":[{"award-number":["82102954"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05149-z","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:36:01Z","timestamp":1778160961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing immunotherapy re-challenge plus chemoradiotherapy versus chemoradiotherapy alone in metastatic esophageal squamous cell carcinoma after first-line immunotherapy failure"],"prefix":"10.1007","volume":"17","author":[{"given":"Jian","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"3","key":"5149_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5149_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"5149_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.medj.2024.05.008","volume":"5","author":"M He","year":"2024","unstructured":"He M, Wang Z, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, et al. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial. Med. 2024;5(9):1137\u201349. e1133.","journal-title":"Med"},{"key":"5149_CR4","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.","journal-title":"BMJ"},{"issue":"10302","key":"5149_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet (London England). 2021;398(10302):759\u201371.","journal-title":"Lancet (London England)"},{"issue":"5","key":"5149_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395.","journal-title":"Lancet Oncol"},{"issue":"6","key":"5149_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"35","key":"5149_CR8","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin oncology: official J Am Soc Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"5149_CR9","doi-asserted-by":"publisher","first-page":"2443811","DOI":"10.1080\/07853890.2024.2443811","volume":"57","author":"X Zhu","year":"2025","unstructured":"Zhu X, Ma X, Li H, Zhang M, Cheng Y, Wu J, Yu W, Feng W, Zhao L, Li Z, et al. The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced\/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096). Ann Med. 2025;57(1):2443811.","journal-title":"Ann Med"},{"key":"5149_CR10","doi-asserted-by":"publisher","first-page":"114328","DOI":"10.1016\/j.ejca.2024.114328","volume":"212","author":"X Meng","year":"2024","unstructured":"Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, Lu P, Guo Y, Ji Y, Zhang M, et al. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024;212:114328.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5149_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13014-020-01678-1","volume":"15","author":"M Colton","year":"2020","unstructured":"Colton M, Cheadle EJ, Honeychurch J, Illidge TM. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol. 2020;15(1):254.","journal-title":"Radiat Oncol"},{"issue":"3","key":"5149_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-010-0930-1","volume":"60","author":"R Ramakrishnan","year":"2011","unstructured":"Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother. 2011;60(3):419\u201323.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"5149_CR13","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035\u201343.","journal-title":"Nat Med"},{"issue":"6371","key":"5149_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Sci (New York NY). 2018;359(6371):91\u20137.","journal-title":"Sci (New York NY)"},{"issue":"14","key":"5149_CR15","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.3390\/cancers15143564","volume":"15","author":"C Nardin","year":"2023","unstructured":"Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients\u2019 Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancerologie Cutanee, GCC). Cancers (Basel). 2023;15(14):3564.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5149_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","volume":"6","author":"P Ravi","year":"2020","unstructured":"Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, et al. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol. 2020;6(10):1606\u201310.","journal-title":"JAMA Oncol"},{"issue":"5","key":"5149_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/1759-7714.15209","volume":"15","author":"G Lin","year":"2024","unstructured":"Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, Yang F, Zhong W, Zhou C, Zhu B, et al. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac cancer. 2024;15(5):419\u201326.","journal-title":"Thorac cancer"},{"key":"5149_CR18","doi-asserted-by":"publisher","first-page":"112364","DOI":"10.1016\/j.intimp.2024.112364","volume":"137","author":"Z Jin","year":"2024","unstructured":"Jin Z, Cao Y, Lu Z, Liu C, Shen L. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma. Int Immunopharmacol. 2024;137:112364.","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"5149_CR19","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1111\/1759-7714.70131","volume":"16","author":"W Zhao","year":"2025","unstructured":"Zhao W, Zhao N, Cao D. Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study. Thorac cancer. 2025;16(13):e70131.","journal-title":"Thorac cancer"},{"key":"5149_CR20","doi-asserted-by":"publisher","first-page":"109679","DOI":"10.1016\/j.radonc.2023.109679","volume":"184","author":"W Zhao","year":"2023","unstructured":"Zhao W, Ke S, Cai X, Zuo Z, Shi W, Qiu H, Cai G, Gong Y, Wu Y, Ruan S, et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial. Radiother Oncol. 2023;184:109679.","journal-title":"Radiother Oncol"},{"issue":"5","key":"5149_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"key":"5149_CR22","doi-asserted-by":"publisher","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","volume":"85","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Rezaeyan A, Najafi M. Abscopal effect in radioimmunotherapy. Int Immunopharmacol. 2020;85:106663.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"5149_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276\u201382.","journal-title":"JAMA Oncol"},{"issue":"10405","key":"5149_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet (London England). 2023;402(10405):871\u201381.","journal-title":"Lancet (London England)"},{"issue":"6","key":"5149_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1667\/RADE-20-00237.1","volume":"195","author":"PA Clark","year":"2021","unstructured":"Clark PA, Sriramaneni RN, Bates AM, Jin WJ, Jagodinsky JC, Hernandez R, Le T, Jeffery JJ, Marsh IR, Grudzinski JJ, et al. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain. Radiat Res. 2021;195(6):522\u201340.","journal-title":"Radiat Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05149-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:09:45Z","timestamp":1782868185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5149"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05149-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Renmin Hospital of Wuhan University (WDRY2023K-K094). The study was performed in accordance with the Declaration of Helsinki and adhered to the Guidelines for Good Clinical Practice. Given the retrospective nature of the study, the Ethics Committee of Renmin Hospital of Wuhan University waived the informed consent requirement under national retrospective study guidelines. All personal identifiers of patients were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"956"}}